Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Neuroendocrine Tumors × talazoparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 25 Triple Negative Breast Neoplasms 12 Prostatic Neoplasms 11 Ovarian Neoplasms 10 Neoplasms 8 Neoplasm Metastasis 8 Leukemia, Myeloid, Acute 5 Fallopian Tube Neoplasms 5 Small Cell Lung Carcinoma 4 Endometrial Neoplasms 4 Colorectal Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Advanced Solid Tumors 4 Pancreatic Neoplasms 3 Stomach Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma, Ewing 2 Recurrence 2 Neuroectodermal Tumors, Primitive, Peripheral 2 Carcinoma, Renal Cell 2 Carcinoma, Ovarian Epithelial 2 mCRPC 1 Wilms Tumor 1 Vaginal Neoplasms 1 Uterine Cervical Neoplasms 1 Triple Negative Metastatic Breast Cancer 1 Thrombocythemia, Essential 1 Solid Tumor 1 Sarcoma 1 Rhabdomyosarcoma 1

Interventions

lutetium Lu 177 dotatate 33 Everolimus 29 Magnetic Resonance Spectroscopy 13 lanreotide 12 gallium Ga 68 dotatate 12 Temozolomide 11 Octreotide 11 Capecitabine 11 Nivolumab 10 177Lu-octreotide, DOTA(0)-Tyr(3)- 10 surufatinib 8 pembrolizumab 8 cabozantinib 8 Positron Emission Tomography Computed Tomography 8 3-Iodobenzylguanidine 8 Sunitinib 7 Specimen Handling 7 amino-acid, glucose, and electrolyte solution 6 90Y-octreotide, DOTA-Tyr(3)- 6 pasireotide 5 Lutetium-177 5 Fluorodeoxyglucose F18 5 Carboplatin 5 Bevacizumab 5 olaparib 4 avelumab 4 Somatostatin 4 Ipilimumab 4 Injections 4 Etoposide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05053854 2025-02-20

PARLuNET

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡